Table 1.
Clinical characteristics, laboratory data, pulmonary function tests, and disease activity in patients with systemic lupus erythematosus related interstitial pneumonia.
| n = 55 (median (range)) | |
|---|---|
| Age at the diagnosis of IP, year-old | 54 (13, 79) |
| Sex, male/female | 13/42 |
| Observation period, month | 85 (0, 346) |
| Smoking | |
| current/ex/never | 4/12/39 |
| Motive for visit | |
| symptoms/medical check-up/referral from other departments/others | 25/3/25/2 |
| Onset order | |
| preceding IP/preceding SLE/concomitant | 7/21/27 |
| Preceding treatments +/− | 26/29 |
| Surgical lung biopsy, n (%) | 9 (16.4%) |
| Comorbid other CTDs, n (%) | 19 (34.5%) |
| Types of comorbid other CTDs | SjS 9, RA 4, SSc 1, DM 1, PMR 1, SSc + SjS 2, SSc + RA 1 |
| Biochemistry test | |
| LDH, U/L | 245 (50, 1327) |
| KL-6, U/ml | 580 (125, 5014) |
| SP-D, ng/ml | 88.5 (17.2, 531.3) |
| Pulmonary function tests | |
| FVC, L | 2.34 (1.20, 4.53) |
| FVC, % predicted | 84.9 (36.6, 130.1) |
| FEV1/FVC, % | 81.8 (56.2, 98.6) |
| DLCO, % predicted | 57.4 (29.0, 98.8) |
| Resting PaO2, mm Hg | 79.7 (55.0, 108.0) |
| Distance in 6MWT, m | 449 (300, 590) |
| Minimum SpO2 in 6MWT, % | 91 (78, 94) |
| SLEDAI-2K | 12 (0, 41) |
Abbreviations; IP: interstitial pneumonia, CTD: connective tissue disease, SjS: sjogren syndrome, RA: rheumatoid arthritis, SSc: systemic sclerosis, PMR: polymyalgia rheumatica, LDH: lactate dehydrogenase, KL-6: Krebs von den Lungen-6, SP-D: surfactant protein D, FVC: forced vital capacity, FEV1: forced expiratory volume in one second, DLCO: diffusion lung capacity for carbon monoxide, 6MWT: 6-minute walk test, SLEDAI-2K: systemic lupus erythematosus disease activity index 2000.